Experience With Brivaracetam in the Acute Care Setting at a Large Tertiary Care Center
BRV appears safe, well-tolerated, and efficacious for acute, inpatient management of RPP, seizures, and SE. Prospective studies validating these findings and directly comparing BRV with other ASMs are warranted.
Authors
- Gabriella Garcia
- Justine Cormier
- Abdalla Ammar (ORCID: https://orcid.org/0000-0002-1427-1173)
- Thanujaa Subramaniam (ORCID: https://orcid.org/0000-0001-8034-3553)
- Christopher Traner
- Lawrence J. Hirsch
- Emily J. Gilmore
Institutions
- Hartford Hospital (US)
- Cleveland Clinic (US)
- NewYork–Presbyterian Hospital (US)
- John Brown University (US)
- Cornell University (US)
- New York Hospital Queens (US)
- Yale University (US)
- Weill Cornell Medical College in Qatar (QA)
Publication Details
- Journal
- The Neurohospitalist
- Published
- 2026-02-02
- DOI
- https://doi.org/10.1177/19418744261422335
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00